机构：[1]Institute of Life Sciences, Wenzhou University, Wenzhou, 325035, China.[2]Biomedical Collaborative Innovation Center of Zhejiang Province & Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Biomedical Collaborative Innovation Center of Wenzhou, Wenzhou, Zhejiang, 325035, China.[3]Sichuan Provincial Center for Mental Health, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, 610072, China.四川省人民医院[4]Chongqing Business Vocational College, Chongqing, 401331, China.[5]Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China.
Cancer remains a daunting and cureless disease, which is responsible for one-sixth of human deaths worldwide. These mortality rates have been expected to rise in the future due to the side effects of conventional treatments (chemotherapy, radiotherapy, and surgery), which can be addressed by applying nanomedicine. In order to escape from biological barriers, such nanomedicine should be mimicked and designed to be stealthy while navigating in the bloodstream. To achieve this, scientists take advantage of erythrocytes (red blood cells; RBCs) as drug carriers and develop RBC membrane (RBCm) coating nanotechnology. Thanks to the significant advances in nanoengineering, various facile surface functionalization methods can be applied to arm RBCm with not only targeting moieties, but also imaging agents, therapeutic agents, and nanoparticles, which are useful for theranostic nanomedicine. This review focuses on refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.
基金：
Financial support from the National Natural
Science Foundation of China (51603023), Fundamental
Research Funds for Central Universities (2018CDH
B1B08, 2018CDXYSW0023, 106112016CDJXY230002),
Natural Science Foundation of Zhejiang Province
(Grant No.LQ19E010004), the Chongqing Research
Program of Basic Research and Frontier Technology
(cstc2017jcyjAX0186), the Non-profit Central Research
Institute Fund of Chinese Academy of Medical
Sciences (2019PT310020) are gratefully acknowledged.
第一作者机构：[1]Institute of Life Sciences, Wenzhou University, Wenzhou, 325035, China.[2]Biomedical Collaborative Innovation Center of Zhejiang Province & Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Biomedical Collaborative Innovation Center of Wenzhou, Wenzhou, Zhejiang, 325035, China.
共同第一作者：
通讯作者：
通讯机构：[1]Institute of Life Sciences, Wenzhou University, Wenzhou, 325035, China.[2]Biomedical Collaborative Innovation Center of Zhejiang Province & Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Biomedical Collaborative Innovation Center of Wenzhou, Wenzhou, Zhejiang, 325035, China.[5]Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, 400030, China.
推荐引用方式(GB/T 7714)：
Da Sun,Jia Chen,Yuan Wang,et al.Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery[J].THERANOSTICS.2019,9(23):6885-6900.doi:10.7150/thno.36510.
APA：
Da Sun,Jia Chen,Yuan Wang,Hao Ji,Renyi Peng...&Wei Wu.(2019).Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.THERANOSTICS,9,(23)
MLA：
Da Sun,et al."Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery".THERANOSTICS 9..23(2019):6885-6900
医学